USPTO serial 90072104
ARGONAUT
Reviewed by CopyMark Law Group
Reg. 6600090Status 790Renewal
- Filing date
- Status date
- Registration date
- Dec 28, 2021
- Examiner
- EISNACH, MICHAEL PATRICK
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with ARGONAUT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $748*
Plus Government fees of $650
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Patrice P. Jean
ARGONAUT THERAPEUTICS LIMITEDMAGDALEN CENTREOXFORD SCIENCE PARK, ROBERT ROBINSON AVEOXFORD, OX44GAGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Epigenetic drugs for the treatment, diagnosis, detection and prevention of cancer; epigenetic drugs targeting arginine methylation in cancer; pharmaceutical preparations in the nature of inhibitors of arginine methylation for the treatment of cancer; pharmaceutical preparations in the nature of inhibitors of protein arginine methyl-transferase (PRMT) for the treatment of cancer; cancer treatment vaccines; therapeutic vaccines for treating cancer; cancer therapy subsection vaccines; pharmaceutical compounds for the treatment, diagnosis, detection and prevention of cancer; pharmaceutical products, preparations and substances for the treatment, diagnosis, detection and prevention of cancer; biological preparations and substances for the treatment, diagnosis, detection and prevention of cancer | ACTIVE | — |
| 042 | Research and development services in the pharmaceutical and biotechnology fields; medical research and development services in the pharmaceutical and biotechnology fields; scientific research and development services; pharmaceutical research and development services; research and development in the field of epigenetic drugs for the treatment, diagnosis, detection and prevention of cancer; research and development in the field of epigenetic drugs targeting arginine methylation in cancer; research and development in the field of inhibitors of arginine methylation for the treatment of cancer; research and development in the field of inhibitors of protein arginine methyl-transferase (PRMT) for the treatment of cancer; research and development in the field of cancer treatment vaccines, therapeutic vaccines for treating cancer and cancer therapy subsection vaccines; research and development in the field of compounds for the treatment, diagnosis, detection and prevention of cancer; research and development in the field of pharmaceutical products, preparations and substances for the treatment, diagnosis, detection and prevention of cancer; research and development in the field of biological preparations and substances for the treatment, diagnosis, detection and prevention of cancer; consultancy, advisory and information services relating to and connected with the aforementioned services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Argonaut Therapeutics Limited
- Other trademarks owned by Argonaut Therapeutics Limited
- Other trademarks owned by Argonaut Therapeutics Limited
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named ARGONAUT
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 23, 2026 | CANG | CANCELLATION GRANTED NO. 999999 | — |
| Jun 2, 2026 | PETC | CANCELLATION INSTITUTED NO. 999999 | — |
| Dec 28, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 12, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 12, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 22, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 3, 2021 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Sep 3, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 3, 2021 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Sep 3, 2021 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Sep 3, 2021 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Sep 3, 2021 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Aug 12, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 7, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 7, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 7, 2021 | ALIE | ASSIGNED TO LIE | — |
| May 17, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 17, 2020 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 17, 2020 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 17, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 10, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 24, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 28, 2020 | NWAP | NEW APPLICATION ENTERED | — |